-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Central nervous pain is caused by sensory neurological lesions or diseases of the central body.
after a central stroke can occur after a cerebrovascular accident.
common causes of central nervous pain include spinal cord injury (including spinal cord hollow disease), multiple sclerosis, and trauma brain injury.
central pain can be spontaneous or stimulating, and may be associated with mechanical pain hypersensitivity and cold pain hypersensitivity.
Phase III study of central nervous pain after spinal cord injury has reached its main end, the First Third Co., Ltd. announced today.
the study was conducted in Asia (Japan, South Korea and Taiwan, China) in a double-blind manner to assess the efficacy and safety of Mirogabalin and placebo in patients with central nervous pain after 274 cases of spinal cord injury.
the main endpoints of the study, which showed changes in pain scores from baseline to week 14, showed mirogabalin better than a placebo.
addition, no other security concerns were found.
results of the study will be published in academic conferences and publications.
。